$Aortic thoracic neuromodulation in heart failure with preserved ejection fraction$

Aortic thoracic neuromodulation in heart failure with preserved ejection fraction

Abstract The inadequacy of medical therapies for heart failure with preserved ejection fraction (HFpEF) is driving the development of device‐based solutions targeting underlying pathophysiologic abnormalities. The maladaptive autonomic imbalance with a reduction in vagal parasympathetic activity and...

Full description

Bibliographic Details
Main Authors:	Pasquale Paolisso, Amir Dagan, Emanuele Gallinoro, Cristina De Colle, Dario Tino Bertolone, Ana Moya, Martin Penicka, Ivan Degrieck, Marc Vanderheyden, Jozef Bartunek
Format:	Article
Language:	English
Published:	Wiley 2023-02-01
Series:	ESC Heart Failure
Subjects:	Aortic thoracic neuromodulation Heart failure with preserved ejection fraction (HFpEF) Autonomic imbalance Harmony™ system Enopace
Online Access:	https://doi.org/10.1002/ehf2.14136

Similar Items

The role of coronary microvascular dysfunction in the pathogenesis of heart failure with preserved ejection fraction
by: Becker Al-Khayatt, et al.
Published: (2024-05-01)

Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial
by: Bin Dong, et al.
Published: (2022-11-01)

Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
by: Natasha L. Patel‐Murray, et al.
Published: (2024-07-01)

The role of cardiac magnetic resonance imaging in the assessment of heart failure with preserved ejection fraction
by: Clement Lau, et al.
Published: (2022-07-01)

Heart failure outcomes by left ventricular ejection fraction in a contemporary region‐wide patient cohort
by: Johan Sundström, et al.
Published: (2024-06-01)

Worsening effect of testosterone deficiency on males with heart failure with preserved ejection fraction
by: Ahmed Hamam, et al.
Published: (2022-12-01)

Prognostic significance of the HFA‐PEFF score in patients with heart failure with preserved ejection fraction
by: Yohei Sotomi, et al.
Published: (2021-06-01)

Role of ejection fraction in patients at risk for advanced heart failure: insights from the HELP‐HF registry
by: Matteo Pagnesi, et al.
Published: (2024-02-01)

Effects of Continuous Accelerated Pacing on Cardiac Structure and Function in Patients With Heart Failure With Preserved Ejection Fraction: Insights From the myPACE Randomized Clinical Trial
by: Kramer J. Wahlberg, et al.
Published: (2024-01-01)

Diagnostic signature for heart failure with preserved ejection fraction (HFpEF): a machine learning approach using multi-modality electronic health record data
by: Nazli Farajidavar, et al.
Published: (2022-12-01)

Non-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
by: Elisabeth A. Jalink, et al.
Published: (2024-01-01)

Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
by: Stephanie J. Rowe, BBiomed, MD, et al.
Published: (2025-01-01)

Proteomics and Precise Exercise Phenotypes in Heart Failure With Preserved Ejection Fraction: A Pilot Study
by: Ravi V. Shah, et al.
Published: (2023-11-01)

Identifying plasma proteomic signatures from health to heart failure, across the ejection fraction spectrum
by: Karolina Andrzejczyk, et al.
Published: (2024-06-01)

Laboratory and Metabolomic Fingerprint in Heart Failure with Preserved Ejection Fraction: From Clinical Classification to Biomarker Signature
by: Alberto Palazzuoli, et al.
Published: (2023-01-01)

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
by: Mariëlle Scheffer, et al.
Published: (2020-12-01)

Myocardial RNA Sequencing Reveals New Potential Therapeutic Targets in Heart Failure with Preserved Ejection Fraction
by: José M. Inácio, et al.
Published: (2023-07-01)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
by: Paolo Morfino, et al.
Published: (2022-08-01)

Hydrogen Sulfide as a Potential Therapy for Heart Failure—Past, Present, and Future
by: Kyle B. LaPenna, et al.
Published: (2021-03-01)

Right Ventricular‐Vascular Uncoupling Predicts Pulmonary Hypertension in Clinically Diagnosed Heart Failure With Preserved Ejection Fraction
by: Zheng‐Wei Chen, et al.
Published: (2024-01-01)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
by: Arjun K. Pandey, et al.
Published: (2022-04-01)

Heart failure with preserved ejection fraction—Out with the old and out with the new?
by: Luis Tolento Cortes, et al.
Published: (2022-07-01)

Heart Failure With Preserved Ejection Fraction With CKD: A Narrative Review of a Multispecialty Disorder
by: Rahul N. Patel, et al.
Published: (2023-12-01)

A Review of Contemporary and Future Pharmacotherapy for Chronic Heart Failure in Children
by: Bibhuti B. Das
Published: (2024-07-01)

Inflammation as a therapeutic target in heart failure with preserved ejection fraction
by: Zhen Hui Peh, et al.
Published: (2023-06-01)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
by: Mark Sweeney, et al.
Published: (2020-09-01)

The clinical relevance of quality of life in heart failure patients with preserved ejection fraction
by: Masahiro Seo, et al.
Published: (2023-04-01)

Associations of medicine use and ejection fraction with the coexistence of frailty and sarcopenia in a sample of heart failure outpatients: a cross-sectional study
by: Rui Valdiviesso, et al.
Published: (2023-12-01)

Study protocol, randomized controlled trial: reducing symptom burden in patients with heart failure with preserved ejection fraction using ubiquinol and/or D-ribose
by: Janet D. Pierce, et al.
Published: (2018-04-01)

Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis
by: Domenico D'Amario, et al.
Published: (2024-08-01)

Astragaloside IV alleviates inflammation and improves myocardial metabolism in heart failure mice with preserved ejection fraction
by: Xiao Wang, et al.
Published: (2024-11-01)

Validation of heart failure algorithm for diagnosing heart failure with preserved ejection fraction: a meta‐analysis
by: Shu Li, et al.
Published: (2023-08-01)

Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction
by: Dan Yin, et al.
Published: (2023-04-01)

D‐dimer and outcomes in hospitalized heart failure patients across the ejection fraction phenotypes
by: Liyan Huang, et al.
Published: (2022-10-01)

Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF)
by: María Valero-Muñoz, et al.
Published: (2022-08-01)

Dantrolene improves left ventricular diastolic property in mineralcorticoid-salt-induced hypertensive rats
by: Junya Nawata, et al.
Published: (2023-07-01)

Myths and Facts About Heart Failure with Preserved Ejection Fraction: Risk Factors, Longevity, Potential Pharmacological and Exercise Interventions
by: Chung-Lieh Hung, et al.
Published: (2013-03-01)

Sex differences in mortality and hospitalization in heart failure with preserved and mid-range ejection fraction: a systematic review and meta-analysis of cohort studies
by: You Deng, et al.
Published: (2024-01-01)

Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature [version 1; peer review: 2 approved]
by: Chanavuth Kanitsoraphan, et al.
Published: (2021-01-01)

Large Animal Models of Heart Failure: Reduced vs. Preserved Ejection Fraction
by: Christopher J. Charles, et al.
Published: (2020-10-01)